| scholarly article | Q13442814 |
| P50 | author | Bruce R Blazar | Q62070764 |
| Corey S Cutler | Q88708322 | ||
| Haesook T Kim | Q89339175 | ||
| Joseph H Antin | Q89778009 | ||
| Philippe Armand | Q95280463 | ||
| Edwin P Alyea | Q96118072 | ||
| Kathy K Wang | Q103028151 | ||
| Robert J Soiffer | Q114398020 | ||
| John Koreth | Q114404718 | ||
| Sarah Nikiforow | Q114404725 | ||
| Jerome Ritz | Q41590860 | ||
| P2093 | author name string | Vincent T Ho | |
| Alexander T Heubeck | |||
| P2860 | cites work | Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation | Q24537575 |
| Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission | Q24539030 | ||
| Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor | Q24670205 | ||
| Enhanced detergent extraction for analysis of membrane proteomes by two-dimensional gel electrophoresis | Q24812283 | ||
| Prognostic Indications of Elevated MCT4 and CD147 across Cancer Types: A Meta-Analysis | Q26771312 | ||
| B cells in chronic graft-versus-host disease | Q26861706 | ||
| The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease | Q28076264 | ||
| Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation | Q33603172 | ||
| Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation | Q33710708 | ||
| EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival. | Q33747651 | ||
| Current issues in chronic graft-versus-host disease | Q33917187 | ||
| Advances in graft-versus-host disease biology and therapy | Q34031916 | ||
| Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors | Q34312702 | ||
| EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome | Q35000659 | ||
| The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. | Q53632072 | ||
| Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies | Q68545473 | ||
| Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease | Q79961518 | ||
| Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation | Q84379433 | ||
| Anti-Angiotensin type 1 receptor antibodies in chronic graft-versus-host disease | Q87976543 | ||
| Long-term survival and late deaths after allogeneic hematopoietic cell transplantation | Q35023409 | ||
| Ibrutinib treatment ameliorates murine chronic graft-versus-host disease | Q35140097 | ||
| Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria | Q35483810 | ||
| Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. | Q35607308 | ||
| Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma | Q35632281 | ||
| Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation | Q35687151 | ||
| Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans | Q35776453 | ||
| Deficient regulatory B cells in human chronic graft-versus-host disease | Q35799170 | ||
| Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset | Q36220347 | ||
| A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation | Q36471247 | ||
| H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease | Q36637621 | ||
| Transmembrane protein CD9 is glioblastoma biomarker, relevant for maintenance of glioblastoma stem cells | Q36729480 | ||
| Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation | Q36763834 | ||
| Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. | Q36876981 | ||
| Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. | Q37104281 | ||
| Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial | Q37113099 | ||
| Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease | Q37162874 | ||
| Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. | Q37528067 | ||
| Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. | Q38311815 | ||
| Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16]. | Q38698179 | ||
| The effects of CD147 on the cell proliferation, apoptosis, invasion, and angiogenesis in glioma | Q38739580 | ||
| A chimeric antibody targeting CD147 inhibits hepatocellular carcinoma cell motility via FAK-PI3K-Akt-Girdin signaling pathway | Q38937831 | ||
| Chronic graft-versus-host disease: biological insights from preclinical and clinical studies | Q39002164 | ||
| Graft-versus-leukemia reactions after bone marrow transplantation | Q41198977 | ||
| The alpha 3 beta 1 integrin is involved in melanoma cell migration and invasion. | Q41330008 | ||
| Emergent autoimmunity in graft-versus-host disease | Q42194452 | ||
| B-cell-directed therapy for chronic graft-versus-host disease | Q42392792 | ||
| Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes | Q43109001 | ||
| CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. | Q44030095 | ||
| Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses | Q44944214 | ||
| An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface | Q45012664 | ||
| Antibodies against human cytomegalovirus late protein UL94 in the pathogenesis of scleroderma-like skin lesions in chronic graft-versus-host disease | Q47407924 | ||
| Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations | Q47605536 | ||
| A novel therapeutic strategy with anti-CD9 antibody in gastric cancers | Q47727915 | ||
| Targeting cancer cell integrins using gold nanorods in photothermal therapy inhibits migration through affecting cytoskeletal proteins | Q47984457 | ||
| Disruption of cultured cells by nitrogen cavitation. | Q52604822 | ||
| CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling. | Q53362858 | ||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2889-2899 | |
| P577 | publication date | 2017-11-14 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease | |
| P478 | volume | 130 |
| Q55043234 | Adrenal crisis in a 14-year-old boy 12 years after hematopoietic stem cell transplantation. |
| Q98735455 | Anti-Ro52 Autoantibodies Are Related to Chronic Graft-vs.-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation |
| Q91670652 | Molecular Analysis of Goodpasture's Disease Following Hematopoietic Stem Cell Transplant in a Pediatric Patient, Recalls the Conformeropathy of Wild-Type Anti-GBM Disease |
| Q93140219 | Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation |
Search more.